Similarly, co-targeting MEK and SHP2, which is required for RAS activation, has provided clinical utility and impaired cancer cell growth in both in vitro and in vivo settings of KRAS-mutant pancreatic cancer and NSCLC [109] and gastroesophageal cancer [110]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.